Drug intelligence / Profile preview

amygdalin

Development stage
Preclinical
Modality
Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration
Oral, Intravenous, Intramuscular
01

Overview

Amygdalin is a naturally occurring cyanogenic glycoside found in the seeds of many fruits, especially apricots, bitter almonds, apples, peaches, cherries, and plums. It has been promoted as an alternative cancer treatment since the 1950s under various names including laetrile and "vitamin B17," though it is not a vitamin. When metabolized in the body—especially when taken orally—amygdalin is broken down by beta-glucosidase enzymes to produce prunasin and mandelonitrile; these are further hydrolyzed to benzaldehyde and hydrocyanic acid (cyanide), which is highly toxic. The proposed mechanism for anticancer activity involves selective toxicity of cyanide toward cancer cells; however, this theory has not been substantiated in humans or clinical trials. Amygdalin also exhibits anti-inflammatory effects via immunomodulation of Treg cells and inhibition of COX-2/iNOS pathways in animal studies. Despite anecdotal claims for use against cancer or pain relief, there is no reliable evidence supporting its efficacy for any medical condition. Its use carries significant risk due to potential cyanide poisoning[1][2][3][4][5].

Other names
laetrilevitamin B17mandelonitrile-beta-glucuronidemandelonitrile beta-D-gentiobiosidenitrilosidepurasin
02

Targets

ILK (Integrin-linked kinase)BCL-2 (BCL-2 family)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)BGL (beta-Glucosidase)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)CDK2 (Cyclin-dependent kinase 2)NOS2 (Nitric Oxide Synthase 2)

Beyond the preview

Go deeper on amygdalin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on amygdalin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call